Cutaneous hyperpigmentation induced by daclatasvir, sofosbuvir, and ribavirin combination therapy

Authors

  • Narisa Brownell Division of Dermatology, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok
  • Chanat Kumtornrut Division of Dermatology, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok

Keywords:

drug-induced pigmentation, ribavirin, daclatasvir, sofosbuvir

Abstract

A 61-year-old Thai man, with hepatitis C (HCV)-related cirrhosis, who underwent liver transplantation, presented with a 3-month history of generalized skin darkening. He had been treated with daclatasvir (DCV), sofosbuvir (SFV) and ribavirin (RBV) combination therapy for three months before developing skin hyperpigmentation accompanying by nail lunular and oral mucosal hyperpigmentation. The cutaneous pigmentation started to fade two months after drug discontinuation. Other investigations showed no evidences of systemic diseases contributing to cutaneous hyperpigmentation. DCV/SFV/RBV combination has been used as a new treatment for hepatitis C virus. The reported adverse skin reactions from DCV/SFV/RBV are still limited, yet including erythema multiforme and Stevens-Johnson syndrome. At present, there is no reported case of skin hyperpigmentation after using these medications. We describe the first case of cutaneous hyperpigmentation induced by DCV/SFV/RBV combination.

References

1. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001;2:253-62.

2. Krause W. Drug-induced hperpigemntation: a systematic review. J Dtsch Dermatol Ges. 2013;11:644-51.

3. Finch CA, Bellotti V, Stray S, et al. Plasma ferritin determination as a diagnostic tool. West J Med 1986;145:657-63.

4. Gamal N, Gitto S, Andreone P. Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview. J Clin Transl Hepatol 2016;4:336-44.

5. Wang Y, Liu P. A case of erythema multiforme drug eruption associated with erythrodermic psoriasis induced by sofosbuvir and daclatasvir. J Clin Pharm Ther 2017;42:108-10.

6. Tsilika K, Tran A, Trucchi R, et al. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection. JAMA Dermatol. 2013;149:675-7.

7. Weng Y, Tsan M. Interferon and ribavirin-induced oral hyperpigmentation in two Taiwanese patients: case report and literature review. Clin Med Rev Case Rep 2015;2:067.

8. Terheggen F, Frissen J, Weigel H, Schouten I, Brinkman K. Nail, hair and skin hyperpigmentation associated with indinavir therapy. AIDS 2004;18:1612.

9. Singh SK, Rai T. A case of zidovudine induced pigmentation on palms and soles. Indian Dermatol Online J 2014;5:98-9.

10. Obuch ML, Baker G, Roth RI, Yen TS, Levin J, Berger TG. Selective cutaneous hyperpigmentation in mice following zidovudine administration. Arch Dermatol 1992;128:508-13.

11. Zidovudine, Ribavirin, Sofosbuvir, Daclatasvir [internet]. [cited 2017 May 26] . Available from: https://en.wikipedia.org/wiki/Zidovudine, https://en.wikipedia.org/wiki/Ribavirin, https://en.wikipedia.org/wiki/Sofosbuvir, https://en.wikipedia.org/wiki/Daclatasvir.

Downloads

Published

2017-06-01

How to Cite

Brownell, N., & Kumtornrut, C. (2017). Cutaneous hyperpigmentation induced by daclatasvir, sofosbuvir, and ribavirin combination therapy. Thai Journal of Dermatology, 33(2), 173–179. Retrieved from https://he02.tci-thaijo.org/index.php/TJD/article/view/159246

Issue

Vol. 33 No. 2 (2017): April - June

Section

Case Report

License

เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใดๆ

บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นลิขสิทธิ์ของวารสารฯ หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใดๆ จะต้องได้รับอนุญาตเป็นลายลักอักษรจากบรรณาธิการวารสารโรคผิวหนังก่อนเท่านั้น